New Atlas

First oral GLP-1 cuts cardiovascular risk by 14% – and it's now FDA-approved

There's still no oral GLP-1 pill dedicated to treating obesity, however, Novo Nordisk has filed a separate case to the FDA seeking approval for its once-daily oral semaglutide (Wegovy). This decision ...

Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy(R) in a pill*) at ObesityWeek(R) 2025, including demonstrated reductions in cardiovascular risk factors

The MarketWatch News Department was not involved in the creation of this content.-- Post hoc analyses include data showing investigational oral semaglutide 25 mg use was associate ...
Bloomberg L.P.

Novo Jumps Most in Month as Ozempic Beats Older Lilly Drug

Novo Nordisk A/S rose the most in a month after its diabetes blockbuster Ozempic beat Eli Lilly & Co.’s older drug Trulicity in a real-world survey of certain US patients. Medicare patients who took ...
Hosted on MSN

Healthy Returns: A key step forward for Novo Nordisk's GLP-1 pill

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. A closely ...

NOVO NORDISK INC.: Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy in a pill*) at ObesityWeek 2025, including demonstrated reductions in ...

Post hoc analyses include data showing investigational oral semaglutide 25 mg use was associated with improvements in blood sugar control and cardiovascular (CV) risk factors across multiple ...